Copper peptide (GHK-Cu) in animal and human studies
The doses of copper peptide used in research vary widely depending on the research model and mode of administration. Animal studies typically use a range of micrograms to milligrams per kilogram of body weight, while human studies are dominated by topical applications or low systemic exposure rather than precisely defined internal doses. In animal studies, copper peptide was administered by intraperitoneal injection, topical application or using biomaterials, among other means. Reported experimental doses most often range from approximately 0.5 mg/kg to 10 mg/kg in multiple administration regimens. Some mechanistic studies also estimate a total daily exposure of 100-200 mg on a whole body basis (Pickart et al., 2014). In topical animal studies, copper peptide is typically used at low concentrations in formulations that act locally rather than systemically. This approach is common in wound and burn models, where the peptide is delivered via systems such as liposomes, hydrogels or scaffolds to promote tissue regeneration (Wang et al., 2017; Zhou et al., 2021).
In human studies, dosing is less standardised and most commonly relates to topical or cosmetic applications. In clinical studies on wound healing, such as diabetic ulcers, copper peptide has been applied directly to the affected areas rather than administered systemically. For this reason, it is difficult to directly compare doses between studies (Mulder et al., 1994). In newer delivery methods, such as microneedling or intradermal systems, copper peptide has been shown to be removed relatively quickly from the body, meaning that repeated applications or controlled-release systems are necessary to maintain efficacy (Li et al., 2015). Nasal and injectable administration have been studied mainly in preclinical models, particularly neurological ones; however, standardised dosing regimens for humans are lacking for these methods.
From a mechanistic perspective, dose variability arises from the way the copper peptide works in the body. It is rapidly metabolised, strongly binds copper, and acts primarily locally in tissues rather than requiring high blood concentrations. Consequently, efficacy is often achieved at the site of application rather than through high systemic doses. The copper peptide used in research is available through suppliers such as SemaxPolska. It is important to note that doses used in animal studies and experiments do not provide guidelines for safety or efficacy in humans, as standardised clinical dosing has not yet been established.
What concentrations of copper peptide have been used in cosmetic research?
In cosmetic and dermatological research, copper peptide is typically used in low concentrations in topical preparations. Most commonly, these range from approximately 0.01%to 0.1%, although higher concentrations closer to 0.4%have been used in some formulations or research designs. In controlled human studies targeting skin ageing and rejuvenation, these preparations were usually applied twice daily for 8 to 12 weeks. These studies showed improvements in skin thickness, elasticity, and a reduction in the appearance of wrinkles (Pickart & Margolina, 2018; Badenhorst et al., 2016). In placebo-controlled studies, the use of copper peptide led to measurable improvements in skin quality without significant systemic absorption, confirming its local action.
Previous studies have also shown that even low concentrations of copper peptides can stimulate skin remodelling. This is because copper peptide acts as a signalling molecule, initiating biological processes rather than exhibiting a simple dose-response relationship typical of many substances (Reddy et al., 2012). Studies on skin penetration show that copper peptide can pass through the stratum corneum and reach deeper layers, where it influences repair processes even at low concentrations (Hostynek et al., 2010).
From a mechanistic standpoint, lower concentrations are effective because copper peptides regulate gene activity, support collagen production, and influence antioxidant pathways, rather than requiring high systemic exposure. However, it should be noted that differences in formulations, delivery systems, and study designs can impact results, making direct comparisons difficult. Copper peptide used in research and formulations is available through suppliers such as SemaxPolska. Concentrations used in cosmetic research should not be treated as equivalent to medical doses, and the results presented do not constitute confirmed therapeutic effects.
References
- Pickart, L., Vasquez-Soller, M. J., & Margolina, A. (2014). GHK and DNA: Resetting the human genome to health. BioMed Research International, 2014, 151479.
- Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., & Zhang, L. (2017). GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration, 25(2), 280–287.
- Zhou, M., Wu, X., Luo, J., Yang, G., Lu, Y., Lin, S., & Li, Y. (2021). Copper peptide-incorporated 3D-printed silk-based scaffolds promote vascularised bone regeneration. Chemical Engineering Journal, 417, 129327.
- Mulder, G. D., Patt, L. M., Sanders, L., Rosenstock, J., Altman, M. I., Hanley, M. E., & Duncan, G. W. (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration, 2(4), 259–269.
- Li, H., Low, Y. S. J., Chong, H. P., Zin, M. T., Lee, C. Y., & Li, B. (2015). Microneedle-mediated delivery of copper peptide through skin: Challenges and strategies for dermal delivery. Journal of Pharmaceutical Investigation, 45(6), 633–642.
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data. International Journal of Molecular Sciences, 19(7), 1987.
- Badenhorst, T., Svirskis, D., Merrilees, M., & Bolke, L. (2016). Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science, 4(2), 1–8.
- Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part I. Experimental Dermatology, 21(8), 563–568.
- Hostynek, J. J., Dreher, F., & Maibach, H. I. (2010). Human skin retention and penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research, 59(12), 1051–1059.